Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 7 | 13 | +0,44 % | ||
| MINERALYS THERAPEUTICS | 6 | 1 | -2,96 % | ||
| IMMUNITYBIO | 5 | 3 | -1,03 % | ||
| GILEAD SCIENCES | 4 | 5 | +0,05 % | ||
| SAVARA | 4 | - | -3,91 % | ||
| SANA BIOTECHNOLOGY | 4 | - | +8,89 % | ||
| CORVUS PHARMACEUTICALS | 3 | - | +9,09 % | ||
| CG ONCOLOGY | 2 | - | +2,22 % | ||
| GRAIL | 2 | - | 0,00 % | ||
| INCYTE | 1 | 25 | -0,62 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:23 | Community Rückblick: BNTX Personalie: "Das ist der Worst Case, mit dem absolut nicht zu rechnen war" | 481 | wallstreetONLINE | © Foto: Chris Emil Janssen - chris.emil-janssen.deNach dem angekündigten Rückzug der BioNTech Gründer Sahin und Türeci, sowie schwachen Jahreszahlen 2025 rutschte die Aktie ab. Auf wO diskutieren Anleger... ► Artikel lesen | |
| 09:50 | Samstag-Meldung zu BIONTECH SE ADR: Jetzt wird's ernst! | 17 | Maximilian Berger | ||
| 04:26 | BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents | 2 | Insider Monkey | ||
| 01:18 | Cathie Wood's ARK stock trades highlight CRISPR buys, 10x Genomics sells | 2 | Investing.com | ||
| Fr | BofA raises CG Oncology stock price target to $72 on market share outlook | 4 | Investing.com | ||
| Fr | CG Oncology stock rating reiterated at Buy by Truist Securities | 1 | Investing.com | ||
| Fr | Evolus, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Fr | Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs | 1 | Insider Monkey | ||
| Fr | Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings | 1 | Insider Monkey | ||
| Fr | Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension | 2 | Insider Monkey | ||
| Fr | Savara GAAP EPS of -$0.13 | 6 | Seeking Alpha | ||
| Fr | SIGA Technologies - Business strength intact, timing risk overdone | 233 | Edison Investment Research | Following a strong H125, driven by c $85m in TPOXX deliveries, H225 was expectedly softer, which we view as a function of SIGA's inherently lumpy procurement-driven model rather than any deterioration... ► Artikel lesen | |
| Fr | Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data | 3 | Investing.com | ||
| Fr | Jefferies senkt Kursziel für Mineralys Therapeutics wegen Bedenken bei Medikament | 3 | Investing.com Deutsch | ||
| Fr | Jefferies cuts Mineralys Therapeutics price target on drug concerns | 2 | Investing.com | ||
| Fr | ImmunityBio rises after updates on cell therapy programs | 30 | Seeking Alpha | ||
| Fr | IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking | 7 | Zacks | ||
| Fr | ImmunityBio Valuation: Paying 33x Sales for Anktiva | 9 | Zacks | ||
| Fr | IBRX Stock: Anktiva's Approvals and What Comes Next | 3 | Zacks | ||
| Fr | GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy | 42 | FiercePharma |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.